A Study of SYS6020 Injection in Refractory Active Systemic Lupus Erythematosus

Summary

This study aimed to observe the safety and tolerability of SYS6020 in adult participants with refractory active systemic lupus erythematosus, determine the recommended dose (RD) that may be explored for subsequent studies, and preliminly evaluate the clinical efficacy of this product,and explore the pharmacokinetics and immunogenicity of SYS6020 injection in those participants.

Timeline

Start

2024-12-26

Primary completion

2029-01-29

Completion

2029-01-29

Drugs

Indications